2010 Antibody Biology and Engineering Gordon Research Conference
2010年抗体生物学与工程戈登研究会议
基本信息
- 批准号:7796947
- 负责人:
- 金额:$ 0.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-01 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAntibodiesAreaAutoimmunityB-LymphocytesBiologyCellular biologyCollaborationsCommunicable DiseasesComplementDevelopmentEngineeringFosteringGoalsHealthHumanIndustryLeadMalignant NeoplasmsProcessRequest for ProposalsResearchScanningScientistTextTherapeuticTherapeutic antibodiesabstractingantibody engineeringbaseimprovedmeetingsnovelpostersprogramssymposium
项目摘要
DESCRIPTION (provided by applicant):
NOTICE: THIS ABSTRACT WAS EXTRACTED FROM APPLICATION AND HAS NOT BEEN PROOFED BY AN SRA.WHEN THERE ARE PROBLEMS WITH THE APPLICATION SCANNING PROCESS, THE EXTRACTED TEXT MAY BE INCORRECT OR INCOMPLETE.
==================
This proposal requests partial support for a new Gordon Research Conference (GRC) on 'Antibody Biology and Engineering' to be held in Ventura, CA from March 7th-12th, 2010. The broad and long term goal of the meeting is to bring together scientists from both basic B cell biology and antibody engineering to lead to the development of novel and improved antibody-based therapeutics. Our Specific aims are: 1) To develop an interdisciplinary program which will cover areas ranging from mechanistic studies of B cell tolerance to the successful application of antibody therapeutics; 2) To initiate cross- talk and collaborations amongst scientists in different areas of B cell biology and antibody engineering; 3) To provide a forum for open discussion on the current compelling questions in the areas of B cell biology and antibody engineering that will inspire new directions and developments. Towards these aims, we will convene about 40 speakers and discussion leaders who are either recognized experts or more junior 'up-and-coming stars' in their field together with about 130 attendees. Sessions will be organized into topics which will be complemented by four poster sessions in which all attendees will be encouraged to participate. In addition to provoking discussion about multiple facets of antibody biology and engineering, we anticipate that this new conference will develop into an established forum for fostering interdisciplinary interactions between academia and the biopharma industry. The rapidly expanding use of antibodies as therapeutics in cancer, autoimmunity and infectious disease indicates that this conference will have direct relevance to human health. Antibodies represent a rapidly expanding class of therapeutics to treat cancer, autoimmunity, infectious diseases and other illnesses. The Gordon Research Conference on Antibody Biology and Engineering will cover topics that range from basic aspects of B cell biology to the application of therapeutic antibodies. As such, the conference should foster the development of improved and/or novel antibody-based therapeutics.
描述(由申请人提供):
注意事项:本摘要摘自应用程序,未经SRA验证。当应用程序扫描过程出现问题时,提取的文本可能不正确或不完整。
==================
该提案要求对将于2010年3月7日至12日在加利福尼亚州文图拉举行的关于“抗体生物学与工程”的新戈登研究会议(GRC)提供部分支持。会议的广泛和长期目标是汇集来自基础B细胞生物学和抗体工程的科学家,以开发新的和改进的基于抗体的治疗方法。我们的具体目标是:1)发展一个跨学科的计划,涵盖从B细胞耐受性的机制研究到抗体治疗的成功应用; 2)在B细胞生物学和抗体工程的不同领域的科学家之间发起交叉讨论和合作;第三章提供一个论坛,就B细胞生物学和抗体工程领域当前引人注目的问题进行公开讨论,这将激发新的方向,发展理念为了实现这些目标,我们将召集约40名演讲者和讨论领导者,他们要么是公认的专家,要么是他们领域的年轻“后起之秀”,还有约130名与会者。会议将按主题进行组织,并辅以四个海报会议,鼓励所有与会者参加。除了引发关于抗体生物学和工程多方面的讨论外,我们预计这次新会议将发展成为一个促进学术界和生物制药行业之间跨学科互动的既定论坛。抗体作为癌症、自身免疫和传染病治疗剂的迅速扩大的使用表明,这次会议将与人类健康直接相关。抗体代表了治疗癌症、自身免疫、传染病和其他疾病的一类迅速扩大的疗法。戈登抗体生物学和工程研究会议将涵盖从B细胞生物学的基本方面到治疗性抗体应用的主题。因此,会议应促进改进和/或新的基于抗体的治疗方法的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELIZABETH SALLY WARD其他文献
ELIZABETH SALLY WARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELIZABETH SALLY WARD', 18)}}的其他基金
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7847559 - 财政年份:2008
- 资助金额:
$ 0.3万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7522511 - 财政年份:2008
- 资助金额:
$ 0.3万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
8955602 - 财政年份:2008
- 资助金额:
$ 0.3万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7656698 - 财政年份:2008
- 资助金额:
$ 0.3万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
8076708 - 财政年份:2008
- 资助金额:
$ 0.3万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
8274344 - 财政年份:2008
- 资助金额:
$ 0.3万 - 项目类别:
Mechanistic studies of FcRn inhibitors for the treatment of IgG-mediated diseases
FcRn抑制剂治疗IgG介导疾病的机制研究
- 批准号:
7990253 - 财政年份:2008
- 资助金额:
$ 0.3万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 0.3万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 0.3万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 0.3万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 0.3万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 0.3万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 0.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 0.3万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 0.3万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 0.3万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 0.3万 - 项目类别:














{{item.name}}会员




